"The Long Run" Antarctic explorer Ernest Shackleton, if he were alive, would appreciate biotech. Today’s scientific entrepreneurs must be ready for the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina, and resilience, to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Listeners of The Long Run with Luke Timmerman that love the show mention: biotech, luke, drug, would love to see, development, science, industry, needs, questions, content, great podcast, world, listen, bio tech.
The Long Run with Luke Timmerman podcast is an exceptional show that delves into the world of biotech with remarkable depth and insight. Host Luke Timmerman puts in tremendous effort to cover important topics and bring on knowledgeable guests who are truly passionate about making a positive impact in the industry. For anyone interested in the biotech space, this podcast is an absolute must-listen.
One of the best aspects of The Long Run is its ability to humanize the stories behind the science and technology. Especially during these challenging times, hearing about the resilience, determination, and achievements of individuals within the industry provides a wonderful source of inspiration. The human connection fostered through this podcast makes listeners feel a part of the biotech community even when physically apart. Additionally, Luke's interviewing skills are commendable as he expertly asks questions that make complex biotech topics understandable to those who may not be immersed in the field.
While there are many great aspects to The Long Run, there are still some areas for improvement. One suggestion is to focus more on the origin story of companies and interviewees. This would provide a deeper understanding of how these organizations came to be and offer fascinating insights into their early development, which can be highly engaging for listeners. Furthermore, keeping questions short and minimizing leading questions would allow guests to share their perspectives more fully without being overshadowed by the host's own opinions or ideas.
In conclusion, The Long Run with Luke Timmerman is an invaluable resource for anyone involved in or interested in the biotech industry. From its extensive knowledge base to its impressive network of sources, this podcast offers unparalleled insights into drug development processes while shedding light on the risks and challenges faced by those pushing scientific boundaries forward. Despite a few areas for improvement, this podcast fills a crucial need in providing insightful content that appeals to both laypeople and industry professionals alike.
Marea Therapeutics CEO Josh Lehrer and CSO Ethan Weiss on a new angle of attack against cardiovascular disease and diabetes.
Peyton Greenside, co-founder and CEO of BigHat Biosciences, on machine-learning guided biologic drug discovery.
Kevin Parker, CEO of Cartography Biosciences, on finding new cancer drug targets.
David Roblin, CEO of London-based Relation Therapeutics, on building a techbio discovery company.
Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.
Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.
Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.
Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.
Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.
David Schenkein, general partner at GV, on investing in the future of biotech.
Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.
Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.
Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.
Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.
Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.
Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world.
Sarah Boyce, CEO of San Diego-based Avidity Biosciences, on RNA medicines for rare muscle diseases.
Sean McClain, CEO of Absci, on using AI to speed up biologic drug discovery.
Jeff Stein, CEO of San Diego-based Cidara Therapeutics, on a long-lasting drug against flu.
Abe Ceesay, CEO of Boston-based Rapport Therapeutics, on a precision medicine approach to neuroscience drug discovery.
Jimi Olaghere is one of the first patients to have been functionally cured of sickle cell disease with a CRISPR gene-edited cell therapy.
David Younger and Randolph Lopez, co-founders of A-Alpha Bio, on using synthetic biology and AI to discover new biologic drugs.
Vineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery.
David Liu, professor of chemistry at Harvard University and co-founder of multiple biotech companies, including Beam Therapeutics and Prime Medicine.
Valerie Daggett, founder and CEO of Seattle-based AltPep, on early detection and treatment of Alzheimer's.
Robert Ang, CEO of Cambridge, Mass.-based Vor Bio, on using CRISPR gene editing to alter bone marrow transplants and improve treatment of acute myeloid leukemia.
Rick Young, professor at MIT and co-founder of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics, on studying gene expression for drug discovery.
Jens Eckstein, investment partner at Hevolution Foundation, on investing in healthy aging.
Shelley Force Aldred and Nathan Trinklein, co-founders of Rondo Therapeutics, on the opportunity with bispecific antibodies for cancer.
Jeff Jonker, CEO of San Diego-based Belharra Therapeutics, on the renaissance in small molecule drug discovery.
Nancy Stagliano, CEO of South San Francisco-based Neuron23, on bringing precision medicine to neuroscience drug discovery.
Diana Brainard, CEO of AlloVir, on leading the fight against infectious diseases.
Reid Huber, partner at Third Rock Ventures, on investing in the future of medicine.
Jeff Huber, co-founder and general partner at Triatomic Capital, on his career path in tech, and then biotech.
Lori Lyons-Williams, CEO of Abdera Therapeutics, on developing targeted radiopharmaceuticals for cancer.
Turning the Tables, Rob Perez Interviews Me
Zach Weinberg and Alexis Borisy of Curie.Bio on Freeing the Biotech Founders
Fred Appelbaum, a physician, scientist and leader at the Fred Hutchinson Cancer Center, on 'Living Medicine,' his new book about the development of bone marrow transplantation and the rise of cell therapy.
Colin Hill, co-founder and CEO of Aitia, on digging deep into biological datasets and finding new drug targets.
Yung Lie, president and CEO of Damon Runyon Cancer Research Foundation, on advancing cancer research by supporting young scientists with bold and brave ideas.
Kevin Conroy, CEO of Exact Sciences, on early detection of cancer.
Jodie Morrison, acting CEO of Q32Bio, on becoming a biotech CEO.
Aaron Ring, a scientist at Yale moving to the Fred Hutchinson Cancer Center, on applying immunology and protein engineering for cancer therapy and more.
Deborah Palestrant, partner at 5AM Ventures and head of the 4:59 initiative, on building biotech startups.
John Maraganore, former founding CEO of Alnylam Pharmaceuticals, on his life in biotech and developing RNA interference as a new class of medicine.
Emile Nuwaysir, CEO of Boston-based Ensoma, on developing off-the-shelf in vivo gene editing therapies.
Catherine Stehman-Breen, CEO of Boston-based Chroma Medicine, on developing epigenetic editing therapies.
Eric Dobmeier, CEO of Seattle-based Chinook Therapeutics, on new strategies for treating kidney diseases.
Ryan Watts, CEO of South San Francisco-based Denali Therapeutics, on neuroscience drug discovery and development.
David Hallal, CEO of ElevateBio, on a long career in biotech and the coming 50-year opportunity in cell therapy and gene therapy.
Joanne Smith-Farrell, CEO of Cambridge, Mass.-based Be Biopharma, on Engineered B-Cell Therapies for Cancer & Rare Diseases.
© 2020-2025 Ivy Podcast Discovery LLC
